Lessons in Sleep Science Research: Recent Episodes
ReachMD
There are many factors that contribute to the under-recognition of excessive daytime sleepiness in obstructive sleep apnea, including the underreporting of symptoms. Further complicating this issue is the fact that even with optimized therapy, excessive daytime sleepiness may still persist in patients. So what steps can we take to address these and other barriers? Find out in this Lessons in Sleep Science Research series, which reviews its prevalence, pathophysiology, and strategies for overcoming the challenges that are often faced when managing patients. © 2020 Jazz Pharmaceuticals Inc., a subsidiary of Jazz Pharmaceuticals plc, all rights reserved. US-SLE-2000467 Rev0920 In Partnership with
Host: Andrew Wilner, MD, FACP, FAAN
Guest: Ken Paller, PhD
Lucid dreaming is complex and remains a mystery to many neurologists, but emerging research suggests we may be able to communicate with dreamers in REM sleep. Dr. Andrew Wilner is joined by Dr. Ken Paller, Northwestern University's Director of the Cognitive Neuroscience program and the training program in the Neuroscience of Human Cognition, to discuss his recent research on communicating with lucid dreamers.
Guest: Richard K. Bogan, MD
Emerging science can help us better understand the link between obstructive sleep apnea (OSA) and excessive daytime sleepiness (EDS). While many factors, such as insufficient sleep, medication, or comorbid disorders, can cause your patients with OSA to feel sleepy, chronic sleep disruption and chronic intermittent hypoxia associated with OSA may also contribute to EDS.
Here to discuss the important physiologic changes to gray and white matter that may occur in OSA and lead to EDS is Dr. Richard K. Bogan, Associate Clinical Professor at the University of South Carolina School of Medicine and Chairman and Chief Medical Officer at SleepMed, Inc.
This promotional, non-CME program is intended for U.S. physicians treating OSA.
Dr. Bogan is a paid consultant of Jazz Pharmaceuticals, Inc.
© 2020 Jazz Pharmaceuticals Inc., a subsidiary of Jazz Pharmaceuticals plc, all rights reserved.
Host: Richard K. Bogan, MD
While positive airway pressure is the standard of care treatment for obstructive sleep apnea (OSA), it may not always be enough to address the excessive daytime sleepiness (EDS) that some patients experience. In fact, in one study, up to 34 percent of patients with OSA still reported EDS (Epworth Sleepiness Score ≥10) despite more than 5 hours of CPAP use a night.
Here, Dr. Richard K. Bogan, Associate Clinical Professor at the University of South Carolina School of Medicine and Chairman and Chief Medical Officer at SleepMed, Inc., sheds light on the prevalence of EDS in OSA. Specifically, Dr. Bogan discusses key data that has raised important observations about how commonly EDS may persist even when patients adhere to CPAP therapy.
This promotional, non-CME program is intended for U.S. physicians treating OSA.
Dr. Bogan is a paid consultant of Jazz Pharmaceuticals, Inc.
© 2020 Jazz Pharmaceuticals Inc., a subsidiary of Jazz Pharmaceuticals plc, all rights reserved.
Guest: Paul Doghramji, MD
Excessive daytime sleepiness (EDS) in obstructive sleep apnea (OSA) is frequently underrecognized, as patients may not understand the extent of their sleepiness and EDS does not always correlate with other OSA symptoms. However, it’s important for physicians to identify EDS as it may lead to adverse consequences.
Dr. Paul P. Doghramji, Senior Family Physician at Collegeville Family Practice and Medical Director of Health Services at Ursinus College, discusses identifying EDS and the vital role assessment tools like the Epworth Sleepiness Scale can have in practice.
This promotional, non-CME program is intended for U.S. physicians treating OSA.
© 2020 Jazz Pharmaceuticals Inc., a subsidiary of Jazz Pharmaceuticals plc, all rights reserved.